# HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

> **NCT05360368** · PHASE1 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 24 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HLX07

## Key facts

- **NCT ID:** NCT05360368
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-30
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-02-28
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05360368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05360368, "HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05360368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*